Following last weeks Valproate Stakeholder Network meeting, we contacted Andrew Dillon Chief Executive of NICE (Clinical guidelines) as we were under the assumption that the current NICE guidelines did NOT include the new PREVENT programme for Sodium Valproate.

Today in a response to us they have clarified that the guidelines for Epilepsy and Bipolar have been updated to include the new legislative warnings with regards to Sodium Valproate and Pregnancy.

In 3 years the guidelines for Epilepsy and Bipolar Disorder will be thoroughly reviewed again.